These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Challenges of Assessing Exon 53 Skipping of the Human Engelbeen S; O'Reilly D; Van De Vijver D; Verhaart I; van Putten M; Hariharan V; Hassler M; Khvorova A; Damha MJ; Aartsma-Rus A Nucleic Acid Ther; 2023 Dec; 33(6):348-360. PubMed ID: 38010230 [TBL] [Abstract][Full Text] [Related]
5. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
6. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy. Relizani K; Goyenvalle A Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663 [TBL] [Abstract][Full Text] [Related]
7. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice. Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790 [TBL] [Abstract][Full Text] [Related]
8. The Pharmacokinetics of 2'- Bosgra S; Sipkens J; de Kimpe S; den Besten C; Datson N; van Deutekom J Nucleic Acid Ther; 2019 Dec; 29(6):305-322. PubMed ID: 31429628 [TBL] [Abstract][Full Text] [Related]
9. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108 [TBL] [Abstract][Full Text] [Related]
10. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy. Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911 [TBL] [Abstract][Full Text] [Related]
11. Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy. Verhaart IE; Heemskerk H; Karnaoukh TG; Kolfschoten IG; Vroon A; van Ommen GJ; van Deutekom JC; Aartsma-Rus A Hum Gene Ther; 2012 Mar; 23(3):262-73. PubMed ID: 22017442 [TBL] [Abstract][Full Text] [Related]
12. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice. Hiller M; Spitali P; Datson N; Aartsma-Rus A Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546 [TBL] [Abstract][Full Text] [Related]
13. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. Kemaladewi DU; Hoogaars WM; van Heiningen SH; Terlouw S; de Gorter DJ; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; ten Dijke P; 't Hoen PA BMC Med Genomics; 2011 Apr; 4():36. PubMed ID: 21507246 [TBL] [Abstract][Full Text] [Related]
14. Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model. Yavas A; Weij R; van Putten M; Kourkouta E; Beekman C; Puoliväli J; Bragge T; Ahtoniemi T; Knijnenburg J; Hoogenboom ME; Ariyurek Y; Aartsma-Rus A; van Deutekom J; Datson N PLoS One; 2020; 15(12):e0244215. PubMed ID: 33362201 [TBL] [Abstract][Full Text] [Related]
15. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. Hanson B; Wood MJA; Roberts TC RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516 [TBL] [Abstract][Full Text] [Related]
16. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion. Maruyama R; Yokota T Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536 [TBL] [Abstract][Full Text] [Related]
17. Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Niks EH; Aartsma-Rus A Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976 [TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089 [TBL] [Abstract][Full Text] [Related]
19. Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in Datson NA; Bijl S; Janson A; Testerink J; van den Eijnde R; Weij R; Puoliväli J; Lehtimäki K; Bragge T; Ahtoniemi T; van Deutekom JC Nucleic Acid Ther; 2020 Feb; 30(1):50-65. PubMed ID: 31821107 [TBL] [Abstract][Full Text] [Related]
20. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Dzierlega K; Yokota T Gene Ther; 2020 Sep; 27(9):407-416. PubMed ID: 32483212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]